Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Immunization of sIPV, DTaP, and HepA in Infants
NCT04636827Phase 4Unknown
- Sponsor
- China National Biotec Group
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sabin-strain inactivated polio vaccine, tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine and hepatitis A vaccine (live, attenuated) in poliomyelitis, diphtheria, Tetanus and 2 more (4 arms), sponsored by China National Biotec Group. Primary endpoints: Seroconversion Rate for sIPV, Seroconversion Rate for DTaP and 4 more. Status: unknown.
02
Drugs
sabin-strain inactivated polio vaccinetetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccinehepatitis A vaccine (live, attenuated)
03
Conditions
poliomyelitisdiphtheriaTetanuspertussishepatitis A (HAV)
Beyond the preview
Go deeper on NCT04636827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636827.